HOLLY SHOEMAKER: Open Payments
NPI 1396376596 · GRIFFIN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,713 in 85 payments from 18 companies in 2025. Trend: 2023 $1,446 · 2024 $1,559 · 2025 $1,713
Food & beverage: $1,713
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $245 |
| ABBVIE INC. | 11 | $223 |
| AstraZeneca Pharmaceuticals LP | 10 | $193 |
| PFIZER INC. | 9 | $171 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $144 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $106 |
| Lundbeck LLC | 4 | $105 |
| Otsuka America Pharmaceutical, Inc. | 4 | $100 |
| Amgen Inc. | 6 | $92 |
| Vanda Pharmaceuticals Inc. | 4 | $92 |
Products named: REXULTI, Ozempic, VRAYLAR, Kerendia, AIRSUPRA, CAPLYTA, ELIQUIS, FANAPT.
Industry payments across GA — which companies pay providers there.
